- Home
- ANAB vs HLF Comparison
ANAB vs HLF Comparison
Compare ANAB & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- HLF
- Stock Information
- Founded
- ANAB 2005
- HLF 1980
- Country
- ANAB United States
- HLF United States
- Employees
- ANAB N/A
- HLF N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- HLF Other Pharmaceuticals
- Sector
- ANAB Health Care
- HLF Health Care
- Exchange
- ANAB Nasdaq
- HLF Nasdaq
- Market Cap
- ANAB 951.1M
- HLF 877.4M
- IPO Year
- ANAB 2017
- HLF N/A
- Fundamental
- Price
- ANAB $36.12
- HLF $8.02
- Analyst Decision
- ANAB Buy
- HLF Strong Buy
- Analyst Count
- ANAB 12
- HLF 4
- Target Price
- ANAB $59.30
- HLF $11.50
- AVG Volume (30 Days)
- ANAB 365.9K
- HLF 1.2M
- Earning Date
- ANAB 10-31-2025
- HLF 11-05-2025
- Dividend Yield
- ANAB N/A
- HLF N/A
- EPS Growth
- ANAB N/A
- HLF 285.96
- EPS
- ANAB N/A
- HLF 3.17
- Revenue
- ANAB $123,164,000.00
- HLF $4,928,500,000.00
- Revenue This Year
- ANAB $24.36
- HLF $1.02
- Revenue Next Year
- ANAB N/A
- HLF $4.52
- P/E Ratio
- ANAB N/A
- HLF $2.53
- Revenue Growth
- ANAB 304.17
- HLF N/A
- 52 Week Low
- ANAB $12.21
- HLF $5.04
- 52 Week High
- ANAB $38.39
- HLF $10.83
- Technical
- Relative Strength Index (RSI)
- ANAB 72.97
- HLF 33.35
- Support Level
- ANAB $33.01
- HLF $8.50
- Resistance Level
- ANAB $35.58
- HLF $8.89
- Average True Range (ATR)
- ANAB 1.67
- HLF 0.30
- MACD
- ANAB -0.05
- HLF -0.05
- Stochastic Oscillator
- ANAB 68.61
- HLF 3.67
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About HLF Herbalife Ltd.
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.